the risks and benefits in a given patient. Future research in this direction with double-blinded case-controlled studies is required to investigate this further.
Introduction
Lumbosacral radiculoplexus neuropathy (LRPN) is an uncommon but distinct condition characterized by asymmetrical lower extremity pain, weakness and muscle atrophy affecting commonly the thigh muscles; mild sensory symptoms are seen. Though originally described in patients with diabetes, more recently it has also been recognized in non-diabetic patients. [1] The pathogenesis is thought to be a result of microvasculitis and resultant ischemic injury to the lumbosacral roots, plexus and / or peripheral nerves. [2] A similar syndrome has also been described in the thoracic nerve roots (i.e. thoracic radiculoneuropathy) and the brachial plexus (i.e. cervical radiculoplexus neuropathy). [3] In spite of its often monophasic and subacute course, it can be associated with significant morbidity due to debilitating pain and residual weakness. [4] [5] [6] Burns originally described this condition in diabetic patients in 1890. [7] Subsequently, Garland re-described it and coined the terms " diabetic myelopathy" (1953) [8] and "diabetic amyotrophy" (1955) . [9, 10] Since then, it has been known by various names including the BurnsGarland syndrome, [4] diabetic polyradiculopathy, [5] femoral and femoral-sciatic neuropathy of diabetes, [11, 12] proximal diabetic neuropathy, [13] diabetic lumbosacral plexopathy [14] etc. Currently, the term 'diabetic lumbosacral radiculoplexus neuropathy' (DLRPN) is preferred by many authors as it broadly encompasses the various theories regarding anatomical localization and pathophysiology. [2] In contrast to DLRPN, LRPN affecting the non-diabetic patients is a recently recognized condition with clinical features, pathogenesis and prognosis similar to its diabetic counterpart. [1, 15] 
Materials and Methods
Literature in English published between 1953 and 2008 was searched in MEDLINE and Pubmed database maintained by the US National library of medicine and National institutes of health, using key words diabetic amyotrophy, lumbosacral radiculoplexus neuropathy, diabetic proximal neuropathy, diabetic radiculopathy and diabetic lumbosacral plexopathy. In addition, the literature reported in various textbooks for peripheral neuropathy and data presented at the Academy of Neurology annual meeting was reviewed.
Clinical presentation
The clinical features of DLRPN and LRPN are essentially indistinguishable except for the presence of diabetes mellitus. [15] [16] [17] Patients are commonly middle-aged but can be older. Patients with DLRPN reported by Coppack et al., ranged between 46 to 71 years of age at the time of onset of symptoms with mean age being 62 years [18] , whereas those reported by Subromony and Wilbourn ranged from 35 to 84 years. [19] Dyck et al., reported 33 cases of DLRPN with onset between 35.8 and 75.9 years with a median age of 65.4 years. [2] In their series of 57 patients with non-diabetic LRPN, median age was about 65 years with the age of onset ranging between 27.8 to 86.5 years. [2] The illness is commonly preceded by unintentional weight loss of more than 10 lbs. [17] In cases of DLRPN, patients usually have Type II diabetes, although in some cases, diabetes comes to light only after the initial presentation of neuropathy. In comparison to patients with diabetic polyneuropathy patients with DLRPN tend to have diabetes that is better controlled and of shorter duration, have lower body mass index, are less likely to be on insulin and have fewer systemic complications like nephropathy or retinopathy. [2] This is consistent with the suggestion that the pathogenesis of DLRPN is independent of the severity and duration of hyperglycemia and the resultant metabolic derangements.
The characteristic presentation is of acute or subacute onset of severe, asymmetrical lower extremity pain and paresthesias involving the anterolateral thigh region. [9, 10, 18, 19] Some patients may report concomitant lower back pain. [2] Pain is described as deep aching, lancinating or burning and tends to be worse at night or on contact with clothes or bed sheets (contact allodynia). [2] Sensory examination reveals hypoesthesia on the anterolateral aspect of the thigh and inner aspect of the leg. [2] Approximately 50% of patients have concomitant length-dependent sensorimotor polyneuropathy with distal sensory loss. [5, 9, 10] Pain is followed by weakness that evolves over weeks to months, commonly affecting the proximal thigh (quadriceps and iliopsoas) muscles. Weakness in sciatic distribution is reported [1] but is less common early in the disease compared to the proximal weakness. [13, 19] Patients commonly complain of difficulty climbing stairs, rising from low chairs and buckling of the knee with weightbearing. Later in the course of the illness, pain and weakness may spread to distal leg segments (foot drop) and to the contralateral extremity. [8, 19, 20, 21] Early wasting of the quadriceps muscle and absence or reduction of the patellar reflex are common features. [9, 10] In addition, during the course of the illness, patients may develop autonomic impairment manifested as orthostatic intolerance and changes in sphincter control. [2] In summary, all classes of nerve fibers including motor, sensory and autonomic tend to be involved.
Diagnostic tests
A high index of suspicion is important in making a clinical diagnosis. These patients are often misdiagnosed as having compressive lumbosacral polyradiculopathy that is often supported by the "incidental" finding of spondylotic changes in the lumbosacral spine. Acute onset of pain in the area of the thigh with weakness in the femoral distribution and absence of the knee reflex in a diabetic patient can rarely be attributed to compressive radiculopathy. Electrodiagnostic testing may be useful to confirm the diagnosis but if done early in the disease process may be non-diagnostic. The nerve conduction studies in affected nerves show reduced compound muscle action potential (CMAP) amplitudes and absent or reduced sensory responses with proportionate slowing of the conduction velocities indicative of an axonal process. [2, 15] The femoral nerve is commonly affected resulting in reduced femoral CMAP amplitude. [19] Approximately 50% of patients with DLRPN may have a concomitant generalized polyneuropathy and more diffuse electrophysiological abnormalities compared to nondiabetic patients. [5, 6, 15, 19] Electromyography (EMG) of affected muscles shows changes of acute denervation in the form of positive sharp waves and fibrillation potentials. Assessment of the voluntary motor unit action potentials (MUAPs) in the acute phase may reveal reduced recruitment, whereas in chronic cases reinnervation changes consisting of high amplitude, long duration, and polyphasic MUAPs with reduced recruitment are commonly seen. [5, 19] The disease process tends to be multifocal and asymmetric. [5] Most severe changes are seen in the lumbar myotomes affecting the quadriceps, iliopsoas and thigh adductors. [19] Lumbar and thoracic paraspinal muscles [15, 19] may also show fibrillation potentials. [2, 5] In addition, electrophysiological abnormalities may also be seen in segments that are not clinically involved including cervical or lumbosacral segment. [15, 19] Abnormal quantitative sensory and autonomic testing in the affected lower extremity can be seen in both DLRPN and LRPN but is rarely useful in making a diagnosis. [2] Similarly, laboratory testing shows changes consistent with diabetes but no other specific diagnostic clues. Patients with DLRPN have increased levels of random blood glucose and glycosylated hemoglobin levels. Also, a significant number of patients with LRPN and normal fasting blood glucose levels may have impaired glucose tolerance either at the time of presentation or a few months after diagnosis. [22] In addition, erythrocyte sedimentation rates (ESR) may be elevated in both forms of LRPN. [14, 15] Occasionally, patients may have reactive rheumatoid factor and antinuclear antibodies which are of uncertain relationship to the disease. [15] Cerebrospinal fluid (CSF) protein may be elevated, especially if there is involvement of the nerve roots. A median value of 89.5 mg/dl (range, 44-214 mg/dl) in the DLRPN cohort and 66.5 mg/dl (range, 18-283 mg/dl) in the non-diabetic LRPN patients has been reported. [2] Radiological investigations such as magnetic resonance imaging (MRI) of the lumbosacral spine and plexus are useful in ruling out other potential etiologies such as compressive polyradiculopathy, infiltrative plexopathy or compression of the plexus by a hematoma, tumor mass etc. Nevertheless, enhancement of lumbosacral nerve roots and plexus [23] may also be seen in both DLRPN and LRPN.
Pathogenesis
The understanding of the pathogenetic mechanisms of DLRPN has evolved over time. Earlier authors believed that the metabolic derangement and vasculopathy that occurs in diabetes played a major role in pathogenesis. [13, 24, 25] Recent studies indicate that the pathogenesis of DLRPN is independent of these metabolic factors and that it is primarily an immune-mediated process. However, the question whether metabolic derangement in diabetes alters the blood nerve barrier, thereby making it more susceptible to immune-mediated injury remains unresolved. [26, 27] Pathological findings in distal cutaneous sensory nerves (sural, superficial peroneal and saphenous) [14, 16, 17, 28] and proximal cutaneous nerves (intermediate cutaneous nerve of the thigh) [29, 30] reported in various studies primarily show multifocal areas of patchy inflammation or vasculitis affecting small caliber neural blood vessels, secondary nerve ischemia with axonal degeneration and focal demyelination in the affected area. Given the chronic and progressive pathogenesis, changes in the nerve consist of areas of active axonal degeneration, empty nerve strands, perineural scarring as well as regeneration changes in the form of injury neuroma and epineurial neovascularization. [17] The detailed findings are summarized and listed in Table 1 .
In addition to this, the role of inflammatory pathogenesis has been further studied by Kelkar et al., [29] who reported that immune-complex and complement deposits are seen at the site of inflammation, and by Kawamura et al., [31] who investigated inflammatory mediators like intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and neural factor κB (NF-κB) in the sural nerve biopsies of 19 patients with DLRPN and 13 patients with non-diabetic LRPN as compared to 20 control subjects. They found upregulation of inflammatory markers ICAM-1, TNF-α, and NK-κB in patients with LRPN, with expression pattern similar to, but less florid than neuropathy associated with systemic vasculitis. Another interesting feature noted was that three patients with higher TNF-α expression clinically had severe pain and acute presentation, which responded well to methylprednisolone. [31] The pathogenesis and pathological changes reported in LRPN are similar to those seen in DLRPN. [16, 31] 
Management
Traditionally, the approach towards the management of DLRPN consisted of symptomatic treatment of pain and tight glycemic control. [18, 32] Part of this was due to reports of eventual recovery of weakness over time and partly due to lack of adequate understanding of the pathophysiology. However, there has been greater recognition recently that the disease can evolve over months with disabling pain and residual weakness. Also, presently the pathogenesis is better understood and appears to be patchy microvasculitis and secondary nerve ischemia, in contrast to the traditionally held belief of it being a metabolic dysfunction of the peripheral nervous system. This has led to the investigation of various immunosuppressive treatment strategies to alter the course of DLRPN.
Immunosuppressants and DLRPN
Various immunosuppressive treatments in the form of prednisone, prednisone in combination with other immunosuppresants (like azathioprine or cyclophosphamide), and intravenous immunoglobulin (IVIG) have been reported with variable outcomes. Preliminary studies were done by Bradley et al., [14] assessing the response to prednisone in three patients and prednisone with cyclophosphamide in two patients with DLRPN. They reported improvement of pain in four and improvement of weakness in two patients.
Similarly, Krendel et al., [33] treated 13 patients with prednisone or IVIG either alone or in combination with azathioprine or cyclophosphamide. All symptoms stopped worsening and there was improvement in strength and activities of daily living in the majority of patients. The interval between the onset of the disease and the institution of the treatment was not mentioned. A retrospective study [16, 34] assessing the use of oral or intravenous pulsed methylprednisolone 500 mg for two days every two weeks for up to three months within one week to five months of onset in nine patients reported dramatic improvement of pain and weakness in seven patients treated within three months of symptom onset. In patients treated at four and five months, improvement was delayed and efficacy was uncertain.
These preliminary efforts prompted institution of a randomized double-blinded multicenter trial, investigating the role of intravenous methylprednisolone in the treatment of DLRPN. [35] A significant difference in the primary outcome measure (neuropathy impairment score of the lower limb) was not found, suggesting a lack of efficacy. The lack of efficacy may have been from delay in institution of the treatment in this multicenter study. Even so, there was improvement in pain and positive neuropathic symptoms in the treatment group. A study by Kilfoyle et al., [34] suggests that treatment with pulsed methylprednisolone instituted within three months of symptom onset leads to significant improvement in pain and weakness in the majority of patients. Response to pain occurred within days to weeks and weakness stabilized and improved faster than the natural history of the disease. Treatment after three months was of uncertain benefit but should be tried in patients with progressive weakness or intractable pain.
Regarding the immunosuppressive strategies for nondiabetic LRPN, the data is limited to a few case reports or small patient cohorts. Awerbuch et al., reported no response to prednisone in one patient with idiopathic relapsing LRPN, [36] whereas Verma and Bradley [37] reported improvement with high-dose IVIG (0.8 g/kg/day for five days) in a patient with progressive lumbosacral plexopathy who did not respond to prednisone, regular dose of IVIG or plasmapheresis. Triggs et al., [38] reported improvement of pain and weakness in four patients with idiopathic LRPN with regular dose IVIG ( 0.4 g/kg/day for five days) and in one patient with high-dose IVIG (0.8 g/kg/day for three days) at a mean of 3.8 months from onset. Lastly, Dyck et al., [39] reported 10 patients treated with intravenous methylprednisolone and one patient treated with prednisone at a comparable dose with improvement in pain, weakness and ability to ambulate suggesting efficacy. Treatment was instituted at a median of five months from onset (range 1-48 months).
Role of metabolic factors and treatment
Originally, DLRPN was thought to be related to metabolic derangement and treatment strategies emphasized aggressive glycemic control. However, Bradley et al., [14] reported continued worsening of DLRPN in three patients despite adequate control of diabetes. Other authors as well, reported variable responses to aggressive diabetic control, ranging from marked improvement to significant residual disability. [24, 32] Symptomatic management Given the disabling pain, patients often require narcotic analgesics in the acute phase with or without other agents used in chronic neuropathic pain like anti-epileptics and tricyclic antidepressants. Physical therapy may be beneficial after the progressive phase of the illness. [26] 
Natural course of Illness and prognosis
Coppack et al., [18] studied the natural course of DLRPN in 27 patients and reported spontaneous recovery in all patients. Mean time to recovery was about three months (range 1-12 months) and recovery was generally complete by 18 months. Pain was the first symptom to remit, usually within a few weeks or months. This was followed by a gradual improvement in weakness that was at times incomplete with residual thigh weakness. Despite residual weakness, disability was minor in the majority of patients. Pascoe et al., [6] studied 21 patients for about three years from the onset of symptoms and found 12 had resumed normal walking, seven ambulated with an aid and two were wheelchair-bound. Recurrence or relapse of the illness Focal areas of immune-complex and complement deposition at their breakdown products the site of cellular infiltration [29] 3. Segmental demyelination clustered in areas of axonal degeneration Patchy inflammation, localized to short segments of the vessel 4. Focal degeneration and scarring of the perineurium Sub-perineurial deposits of hemosiderin indicative of previous bleeding 5. Areas of regenerative changes within or beyond the original fascicle Epineurial neovascularization in areas of fascicular regeneration forming microfasciculi (injury neuroma) can occur but is uncommon. [5, 18] The natural course and prognosis of non-diabetic LRPN is identical to that of DLRPN. [2] Future research Given the paucity of data for treatment of LRPN, a key issue that remains unanswered is the impact of immunosuppression in the acute phase of illness on modifying the disease course, alleviating pain and minimizing residual weakness and disability. This also raises the question of possible ways to better stratify patients who will benefit the most (with minimal adverse effects) as well as optimal intensity and strategies (prednisone vs. IVIG vs. other agents) for immunosuppression. Further randomized controlled clinical trials aimed to answer these questions are warranted.
Conclusion
DLRPN and non-diabetic LRPN is a self-limiting condition. Newer insights into the pathogenesis allude to an underlying immune-mediated process. Early institution of immunosuppressive treatment may have a potential role in the management of DLRPN and LRPN. However, the data is limited to small patient cohort studies and case reports. There have been no randomized controlled clinical trials or large cohort studies to demonstrate its efficacy adequately. Hence, the decision to initiate immunosuppression should be individualized considering the clinical presentation, relative acuity and time between symptom onset (less than three months), extent of disability and severity of symptoms, as well as the risks and benefits in a given patient. Further controlled studies analyzing the role of early treatment with immunosuppressant medications are needed to establish its role with certainty.
